Vyvanse and Movantik drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vyvanse (lisdexamfetamine dimesylate) and Movantik (naloxegol oxalate). Common drug interactions include dysphagia among females and hospitalisation among males.

The phase IV clinical study analyzes what interactions people have when they take Vyvanse and Movantik. It is created by eHealthMe based on reports of 28 people who take the same drugs from the FDA, and is updated regularly.

What is Vyvanse?

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 35,868 Vyvanse users. Check the latest studies of Vyvanse.

What is Movantik?

Movantik has active ingredients of naloxegol oxalate. It is often used in constipation. eHealthMe is studying from 3,523 Movantik users. Check the latest studies of Movantik.

On Jul, 09, 2026

28 people who take Vyvanse and Movantik together, and have interactions are studied.

What are the common drug interactions of Vyvanse and Movantik, by gender? *:

female:

Dysphagia (a condition in which swallowing is difficult or painful)
Staphylococcal infection (an infection with staphylococcus bacteria)
Fall
Cataplexy (loss of muscle tone accompanied by full conscious awareness)
Dyskinesia (abnormality or impairment of voluntary movement)
Memory impairment
Muscle tightness
Abdominal pain upper
Anger
Influenza

male:

Hospitalisation
Hepatic enzyme increased
Tinnitus (a ringing in the ears)
Hypertension (high blood pressure)
Nasopharyngitis (inflammation of the nasopharynx)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Agitation (state of anxiety or nervous excitement)
Craniocerebral injury (injury to cranium and brain)
Migraine (headache)
Overdose

What are the common drug interactions of Vyvanse and Movantik, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Abdominal pain upper
Anger
Influenza
Hospitalisation
Migraine (headache)
Agitation (state of anxiety or nervous excitement)
Craniocerebral injury (injury to cranium and brain)
Hepatic enzyme increased
Overdose
Seizure (abnormal excessive or synchronous neuronal activity in the brain)

40-49:

Abdominal pain
Adverse event
Blindness unilateral
Diarrhoea
Foot fracture
Furuncle (infection of the hair follicle)
Hepatic vein thrombosis (obstruction in the veins of the liver caused by a blood clot)
Hospitalisation
Hunger
Limb injury

50-59:

n/a

60+:

Cataplexy (loss of muscle tone accompanied by full conscious awareness)
Dyskinesia (abnormality or impairment of voluntary movement)
Memory impairment
Muscle tightness
Dysphagia (a condition in which swallowing is difficult or painful)
Spinal osteoarthritis (joint cartilage loss in spine)
Cardiac failure congestive
General physical health deterioration (weak health status)
Quality of life decreased
Therapeutic response unexpected

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 24 people, 85.71%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 24 people, 85.71%
Drowsiness: 7 people, 25.00%
Depression: 5 people, 17.86%
Neuropathy Peripheral (surface nerve damage): 4 people, 14.29%
Intervertebral Disc Degeneration (spinal disc degeneration): 4 people, 14.29%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 14.29%
Pain: 3 people, 10.71%
Stress And Anxiety: 2 people, 7.14%
Migraine (headache): 2 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Vyvanse and Movantik?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously